NOS2 and neoplasm: Notably, these results are consistent with a recent phase I/II clinical trial demonstrating remodeling of the tumor immune microenvironment that involved increased B cells and neutrophils as well as improved overall survival and complete pathologic responses in patients with chemoresistant TNBC treated with Taxol and the NOS inhibitor, L-NMMA (12).